Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.
about
A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporterTherapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver diseasePhenocopy--a strategy to qualify chemical compounds during hit-to-lead and/or lead optimizationThe use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentPredicting in vivo drug interactions from in vitro drug discovery data.Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsyRational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.Liver enzyme induction and inhibition: implications for anaesthesia.Interactions of herbs with cytochrome P450.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo.Active-site structure, binding and redox activity of the heme-thiolate enzyme CYP2D6 immobilized on coated Ag electrodes: a surface-enhanced resonance Raman scattering study.Metabolism and transport of oxazaphosphorines and the clinical implications.Application of chimeric mice with humanized liver for predictive ADME.Cytochrome P450 reaction-phenotyping: an industrial perspective.Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects.Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.Advances in predicting CYP-mediated drug interactions in the drug discovery setting.Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models.The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.A High-Throughput (HTS) Assay for Enzyme Reaction Phenotyping in Human Recombinant P450 Enzymes Using LC-MS/MS.A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?Quantitative assessment of the influence of cytochrome P450 2C19 gene polymorphisms and digestive tract cancer risk.Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation.Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver.
P2860
Q28219109-0AB0D46B-2E5E-4863-946C-8141C381A7BAQ28472958-B5B7D0A1-F73B-42E2-9B0B-DEDF37349692Q28476479-6372653B-4A86-4C5A-9BA9-3E4DB9FBC06AQ30977143-FDB6C3D1-0966-431A-A01A-E94EBDC6C2B1Q31011412-BDCE35BE-E2C2-4600-8381-0681210FFB0CQ34169804-3CA597C1-649E-469C-BF27-37FD08E79D07Q34233142-232879FB-5C3D-47C6-9A10-A18DA6E45947Q34487131-557768C8-8331-4355-B769-1006CFE9F203Q35085032-2B792CD5-2AE9-4737-A0E0-2D835FBD82C4Q35873687-8209A2C7-920F-4C01-8D7E-123F6E04B814Q36061821-C7D86693-26FE-46E8-84DA-27E1CA3B2888Q36097183-BCB0E8B5-0CA1-412D-97F0-3060D3E29D1EQ36177204-9B8A87F1-56A4-4141-880C-2789F63320FFQ36360811-83361060-E5C6-4B8E-8B0E-028CBDF723DCQ36761682-9B50A21E-0C34-4FA5-A2AD-43F3C4B99E30Q36960539-29FFC3B2-E558-44B3-B38E-2E19F3BDF925Q37017860-477801D2-F9C7-4940-8273-420D4E018517Q37150887-0A97FF6D-7D03-470F-BDED-5A4FBE9E7B45Q37506391-AB9C5CE3-5362-44C6-8B89-4C550BA92B72Q38089823-86E852DC-F4B8-4300-BDCD-74CBE0B847EFQ38255685-59B6D326-AB81-4CFB-A410-61A0447E4DA7Q39292057-5A885FA4-9729-4694-A5F3-D8AB2DEC6636Q39810172-EAB4475C-B5C6-4821-955A-708D6CAA5385Q40300462-1BACED7E-F3C5-47E4-B315-D4BEB4905C32Q40565875-1D7A813F-FDCA-446C-9B9C-4116E70D3198Q40568343-1CDDC4BC-DC96-48A4-97F5-926EADBB6361Q42284131-FD63F23A-43BA-4E41-B13E-8C391B16B77AQ42936143-8494614B-9A44-4D9F-B667-A78CB3E12B44Q43579724-9CE1D335-1550-4121-A11D-A4E40FA30C9EQ48585391-48C9C2D2-0CC5-4508-A749-39AD87CA0030Q53647531-FD453A09-CEDC-4385-AC2C-E64B1A73B70E
P2860
Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@ast
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@en
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@nl
type
label
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@ast
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@en
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@nl
prefLabel
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@ast
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@en
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@nl
P356
P1476
Cytochrome P450 pharmacogeneti ...... ies and clinical consequences.
@en
P2093
A David Rodrigues
Thomas H Rushmore
P304
P356
10.2174/1389200023337522
P407
P577
2002-06-01T00:00:00Z